Penn spinout Linnaeus Therapeutics secures an additional $1.6M in Funding  

Penn spinout Linnaeus Therapeutics has raised another $1.6 million in financing, bringing its cumulative funding total to over $13 million since 2018.   

Penn Robotics Startup Sahay AI Aims to Make Railroads Safer  

Sahay AI is focused on transforming railway inspections through innovative AI-powered solutions.

Penn Spinout Heirloom Carbon Technologies Secures $475 Million Commitment for North America’s Second Direct Air Capture Facility in Louisiana 

Penn spinout Heirloom Carbon Technologies plans to invest $475 million to build its second Direct Air Capture (DAC) facility in North America, located at the Port of Caddo-Bossier in Louisiana.

Exyn Technologies and Stitch3D Announce Partnership; Exyn Advances AI Aerial Autonomy Technology to Overcome Dust in Underground Mines  

The goal of the collaboration is to to host, manage, view, process and share point cloud data securely directly on the web.  

iECURE included on list of Fierce Biotech’s 2024 Fierce 15  

iECURE was recognized for its innovative approach to treating rare childhood diseases by developing therapies that correct gene function directly inside the body.

Penn Spinout Interius BioTherapeutics Raises Additional $67M and doses first patient

The company’s approach focuses on creating cancer-fighting cells directly inside the body, potentially bypassing the need for external cell manipulation and chemotherapy.

Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases   

Carisma has expanded its collaboration with Moderna to develop two chimeric antigen receptor macrophage (CAR-M) targets for autoimmune disease treatment. 

Tern Therapeutics Launches with $15 Million in Financing and CLN2 Batten Disease Treatment Pipeline from REGENXBIO

Tern Therapeutics, a biotechnology company focused on developing gene therapies for rare diseases, recently launched with $15 million in financing.

Dr. James Wilson takes on roles in two new companies spun out of Penn’s Gene Therapy Program  

James Wilson, MD, PhD, has left Penn after 33 years to take on leadership roles in two independent startups that he co-founded.

Filter

Success Stories

Highlights of the PCI news focused on Penn commercialization accomplishments

All Success Stories
Skip to content